Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986226 |
Synonyms | |
Therapy Description |
BMS-986226 is a monoclonal antibody that targets ICOS (inducible T-cell costimulator, CD278) to activate T-cells in the immune anti-tumor response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986226 | BMS986226|BMS 986226 | BMS-986226 is a monoclonal antibody that targets ICOS (inducible T-cell costimulator, CD278) to activate T-cells in the immune anti-tumor response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03251924 | Phase Ib/II | BMS-986226 + Nivolumab BMS-986226 + Ipilimumab BMS-986226 | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | Terminated | USA | ESP | CHE | CAN | 0 |